Last 12 months
Inside the activity.
0 purchase rows · 29 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 9 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2020 Filed Mar 12, 2020 21:00 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GrantCommon Stock | 4,349 | $106.46 | $462,994.54 |
DisclosureSEC source: 0001022079-20-000077 · wf-form4_158404681478971.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,436 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2017, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:58 UTC |
GUINAN MARKExecutive Vice President & CFO
|
Tax withholdingCommon Stock | 3,870 | $106.46 | $412,000.20 |
DisclosureSEC source: 0001022079-20-000075 · wf-form4_158404671319326.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,579 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:58 UTC |
GUINAN MARKExecutive Vice President & CFO
|
GrantCommon Stock | 7,693 | $106.46 | $818,996.78 |
DisclosureSEC source: 0001022079-20-000075 · wf-form4_158404671319326.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,449 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2017, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:57 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
Tax withholdingCommon Stock | 2,517 | $106.46 | $267,959.82 |
DisclosureSEC source: 0001022079-20-000073 · wf-form4_158404662542081.xml · nonDerivative · entry 2 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,912 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:57 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
GrantCommon Stock | 5,018 | $106.46 | $534,216.28 |
DisclosureSEC source: 0001022079-20-000073 · wf-form4_158404662542081.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,429 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2017, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:55 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 100 | $71.17 Strike: $71.17 | $7,117.00 |
DisclosureSEC source: 0001022079-20-000071 · wf-form4_158404652569875.xml · derivative · entry 5 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,717 Underlying: Common Stock · 100 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 4, 2020. F4 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 23, 2016, the second on February 23, 2017 and the final on February 23, 2018. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:55 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
SaleCommon Stock | 100 | $112.19 | $11,219.00 |
DisclosureSEC source: 0001022079-20-000071 · wf-form4_158404652569875.xml · nonDerivative · entry 4 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,747 F3 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 4, 2020. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:55 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
Exercise / conversionCommon Stock | 100 | $71.17 | $7,117.00 |
DisclosureSEC source: 0001022079-20-000071 · wf-form4_158404652569875.xml · nonDerivative · entry 3 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 4, 2020. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:55 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 13,898 | $106.46 | $1,479,581.08 |
DisclosureSEC source: 0001022079-20-000071 · wf-form4_158404652569875.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,747 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:55 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
GrantCommon Stock | 25,085 | $106.46 | $2,670,549.10 |
DisclosureSEC source: 0001022079-20-000071 · wf-form4_158404652569875.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,645 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2017, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:54 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
Tax withholdingCommon Stock | 277 | $106.46 | $29,489.42 |
DisclosureSEC source: 0001022079-20-000069 · wf-form4_158404643426730.xml · nonDerivative · entry 2 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,977 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. F3 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:54 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
GrantCommon Stock | 837 | $106.46 | $89,107.02 |
DisclosureSEC source: 0001022079-20-000069 · wf-form4_158404643426730.xml · nonDerivative · entry 1 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,253 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2017, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:52 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
Tax withholdingCommon Stock | 2,517 | $106.46 | $267,959.82 |
DisclosureSEC source: 0001022079-20-000067 · wf-form4_158404635563433.xml · nonDerivative · entry 2 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,390 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:52 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
GrantCommon Stock | 5,018 | $106.46 | $534,216.28 |
DisclosureSEC source: 0001022079-20-000067 · wf-form4_158404635563433.xml · nonDerivative · entry 1 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,907 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2017, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:38 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 230,178 | $71.17 Strike: $71.17 | $16,381,768.26 |
DisclosureSEC source: 0001022079-20-000065 · wf-form4_158387269621728.xml · derivative · entry 7 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,817 Underlying: Common Stock · 230,178 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 4, 2020. F7 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 23, 2016, the second on February 23, 2017 and the final on February 23, 2018. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:38 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
SaleCommon Stock | 2,000 | $116.27 | $232,544.00 |
DisclosureSEC source: 0001022079-20-000065 · wf-form4_158387269621728.xml · nonDerivative · entry 6 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,560 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 4, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $116.05 to $116.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:38 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
SaleCommon Stock | 3,937 | $115.45 | $454,534.52 |
DisclosureSEC source: 0001022079-20-000065 · wf-form4_158387269621728.xml · nonDerivative · entry 5 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,560 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 4, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $115.05 to $116.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:38 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
SaleCommon Stock | 16,426 | $114.24 | $1,876,440.54 |
DisclosureSEC source: 0001022079-20-000065 · wf-form4_158387269621728.xml · nonDerivative · entry 4 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,497 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 4, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $114.03 to $114.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:38 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
SaleCommon Stock | 36,790 | $113.65 | $4,181,257.08 |
DisclosureSEC source: 0001022079-20-000065 · wf-form4_158387269621728.xml · nonDerivative · entry 3 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,923 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 4, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $113.03 to $114.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:38 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
SaleCommon Stock | 171,025 | $112.21 | $19,190,202.18 |
DisclosureSEC source: 0001022079-20-000065 · wf-form4_158387269621728.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,713 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 4, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $112.00 to $112.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:38 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
Exercise / conversionCommon Stock | 230,178 | $71.17 | $16,381,768.26 |
DisclosureSEC source: 0001022079-20-000065 · wf-form4_158387269621728.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 4, 2020. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 22:53 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 690 | $109.02 | $75,223.80 |
DisclosureSEC source: 0001022079-20-000063 · wf-form4_158293036468118.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,087 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 24, 2018. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 22:51 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
SaleCommon Stock | 789 | $109.02 | $86,016.78 |
DisclosureSEC source: 0001022079-20-000061 · wf-form4_158293029573669.xml · nonDerivative · entry 3 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,411 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 22:50 UTC |
Davis J. E.EVP, General Diagnostics
|
SaleCommon Stock | 1,100 | $109.02 | $119,922.00 |
DisclosureSEC source: 0001022079-20-000059 · wf-form4_158293022576312.xml · nonDerivative · entry 3 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,105 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 00:22 UTC |
GUINAN MARKExecutive Vice President & CFO
|
Tax withholdingCommon Stock | 1,195 | $112.90 | $134,915.50 |
DisclosureSEC source: 0001022079-20-000057 · wf-form4_158284932517296.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,756 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 00:21 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 4,299 | $112.90 | $485,357.10 |
DisclosureSEC source: 0001022079-20-000056 · wf-form4_158284926106265.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,560 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 00:17 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
Tax withholdingCommon Stock | 98 | $112.90 | $11,064.20 |
DisclosureSEC source: 0001022079-20-000051 · wf-form4_158284902657071.xml · nonDerivative · entry 1 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,416 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 00:19 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
Tax withholdingCommon Stock | 773 | $112.90 | $87,271.70 |
DisclosureSEC source: 0001022079-20-000053 · wf-form4_158284912719230.xml · nonDerivative · entry 1 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,889 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 22:53 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 668 | $112.90 | $75,417.20 |
DisclosureSEC source: 0001022079-20-000063 · wf-form4_158293036468118.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,777 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 22:53 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 321 | $111.09 | $35,659.89 |
DisclosureSEC source: 0001022079-20-000063 · wf-form4_158293036468118.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,445 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 24, 2018. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 22:51 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
Tax withholdingCommon Stock | 777 | $112.90 | $87,723.30 |
DisclosureSEC source: 0001022079-20-000061 · wf-form4_158293029573669.xml · nonDerivative · entry 2 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,200 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 22:51 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
SaleCommon Stock | 368 | $111.09 | $40,881.12 |
DisclosureSEC source: 0001022079-20-000061 · wf-form4_158293029573669.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,977 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 22:50 UTC |
Davis J. E.EVP, General Diagnostics
|
Tax withholdingCommon Stock | 1,187 | $112.90 | $134,012.30 |
DisclosureSEC source: 0001022079-20-000059 · wf-form4_158293022576312.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,205 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 22:50 UTC |
Davis J. E.EVP, General Diagnostics
|
SaleCommon Stock | 510 | $111.09 | $56,655.90 |
DisclosureSEC source: 0001022079-20-000059 · wf-form4_158293022576312.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,392 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:33 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 307 | $113.34 | $34,795.38 |
DisclosureSEC source: 0001022079-20-000047 · wf-form4_158275278608303.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,766 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
Tax withholdingCommon Stock | 49 | $113.34 | $5,553.66 |
DisclosureSEC source: 0001022079-20-000049 · wf-form4_158275292932701.xml · nonDerivative · entry 3 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,514 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC |
Davis J. E.EVP, General Diagnostics
|
Tax withholdingCommon Stock | 552 | $113.34 | $62,563.68 |
DisclosureSEC source: 0001022079-20-000048 · wf-form4_158275283053318.xml · nonDerivative · entry 3 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,902 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC |
Davis J. E.EVP, General Diagnostics
|
SaleCommon Stock | 598 | $112.73 | $67,412.54 |
DisclosureSEC source: 0001022079-20-000048 · wf-form4_158275283053318.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,454 F2 · shares: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
Tax withholdingCommon Stock | 423 | $113.34 | $47,942.82 |
DisclosureSEC source: 0001022079-20-000046 · wf-form4_158275274405274.xml · nonDerivative · entry 2 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,662 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:31 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 2,074 | $113.34 | $235,067.16 |
DisclosureSEC source: 0001022079-20-000045 · wf-form4_158275270122533.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,859 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:31 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
Tax withholdingCommon Stock | 356 | $113.34 | $40,349.04 |
DisclosureSEC source: 0001022079-20-000044 · wf-form4_158275265542037.xml · nonDerivative · entry 3 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,345 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:31 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
SaleCommon Stock | 405 | $112.73 | $45,655.65 |
DisclosureSEC source: 0001022079-20-000044 · wf-form4_158275265542037.xml · nonDerivative · entry 2 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,701 F2 · shares: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:29 UTC |
GUINAN MARKExecutive Vice President & CFO
|
Tax withholdingCommon Stock | 565 | $113.34 | $64,037.10 |
DisclosureSEC source: 0001022079-20-000042 · wf-form4_158275256892243.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,951 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:33 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 382 | $112.17 | $42,848.94 |
DisclosureSEC source: 0001022079-20-000047 · wf-form4_158275278608303.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,073 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:35 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
Tax withholdingCommon Stock | 56 | $112.17 | $6,281.52 |
DisclosureSEC source: 0001022079-20-000049 · wf-form4_158275292932701.xml · nonDerivative · entry 1 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,563 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:34 UTC |
Davis J. E.EVP, General Diagnostics
|
Tax withholdingCommon Stock | 643 | $112.17 | $72,125.31 |
DisclosureSEC source: 0001022079-20-000048 · wf-form4_158275283053318.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,052 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:32 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
Tax withholdingCommon Stock | 515 | $112.17 | $57,767.55 |
DisclosureSEC source: 0001022079-20-000046 · wf-form4_158275274405274.xml · nonDerivative · entry 1 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,085 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:31 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 2,404 | $112.17 | $269,656.68 |
DisclosureSEC source: 0001022079-20-000045 · wf-form4_158275270122533.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,933 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:31 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
Tax withholdingCommon Stock | 432 | $112.17 | $48,457.44 |
DisclosureSEC source: 0001022079-20-000044 · wf-form4_158275265542037.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,106 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:30 UTC |
Mendez Manuel O.SVP & Chief Commercial Officer
|
Tax withholdingCommon Stock | 123 | $112.17 | $13,796.91 |
DisclosureSEC source: 0001022079-20-000043 · wf-form4_158275261294344.xml · nonDerivative · entry 1 Mendez Manuel O. · CIK 0001475995 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,853 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.